Funding
Funding not disclosed
Founders
Product
Problem
The development of effective cancer treatments is hindered by the limitations of traditional 2D cell cultures and animal models, which often fail to accurately replicate the complexity and heterogeneity of human tumors. This can lead to inaccurate drug screening results and a high failure rate in clinical trials.
Solution
This startup offers a platform for generating and analyzing 3D organoid models of tumors, providing a more accurate and predictive preclinical testing environment. Their technology enables the creation of patient-derived organoids (PDOs) that maintain the genetic and phenotypic characteristics of the original tumor. These organoids can be used for high-throughput drug screening, biomarker discovery, and personalized medicine applications, allowing researchers and clinicians to identify the most effective treatment strategies for individual patients. The platform aims to bridge the gap between traditional research methods and clinical outcomes, accelerating the development of targeted cancer therapies.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology firms, academic research institutions, and clinical oncology centers involved in cancer drug discovery, preclinical testing, and personalized medicine.
Features
- Generation of patient-derived organoids (PDOs) that closely mimic the original tumor microenvironment
- High-throughput screening assays for evaluating drug efficacy and identifying potential therapeutic targets
- Advanced imaging and analytical tools for characterizing organoid morphology, gene expression, and drug response
- Customizable organoid models for specific cancer types and research applications
- Scalable platform for generating large numbers of organoids for preclinical studies
- Data analysis and reporting tools for interpreting experimental results and identifying potential biomarkers